Usefulness of Tissue Doppler Imaging‐Myocardial Performance Index in the Evaluation of Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction
Key result
Tissue Doppler imaging-derived myocardial performance index >0.66 was the best independent predictor of cardiovascular death and heart failure admission over a median 32-month follow-up.
Why the study?
Does TDI-MPI predict adverse cardiac events better than conventional echo parameters in patients with diastolic dysfunction or HFPEF?
Population
408 patients who had diastolic dysfunction without heart failure (HF) or HFPEF
Comparison
Evaluation by tissue Doppler imaging-derived… vs Evaluation by mitral flow or conventional echo…
Design
Cohort
Follow-up
median 32 months
Authors
Discussion
Loading...
Member takes
Implication
Supports TDI-MPI for HFpEF prognostication; leaves open prospective validation over conventional parameters.
Study Design
Type
Cohort (n=408)
Structured PICO
Does TDI-MPI predict adverse cardiac events better than conventional echo parameters in patients with diastolic dysfunction or HFPEF?
P
Population
408 patients who had diastolic dysfunction without heart failure (HF) or HFPEF
I
Intervention
Evaluation by tissue Doppler imaging (TDI)-derived myocardial performance index (MPI)
C
Comparator
Evaluation by mitral flow (MF) or conventional echo parameters
O
Outcome
Composite of cardiovascular death and admission for HF at median 32 months follow-upcomposite
TDI-MPI is a useful prognostic parameter for evaluating patients with HFPEF, outperforming conventional mitral flow parameters.
Cite This Study
Kim et al. (2011) conducted a cohort in Diastolic dysfunction and heart failure with preserved ejection fraction (HFPEF) (n=408). Tissue Doppler imaging-derived myocardial performance index (TDI-MPI) vs. Mitral flow (MF) parameters was evaluated on Composite of cardiovascular death and admission for heart failure. Tissue Doppler imaging-derived myocardial performance index >0.66 was the best independent predictor of cardiovascular death and heart failure admission over a median 32-month follow-up.